CN113057329A - Glucoraphanin functional food composition - Google Patents
Glucoraphanin functional food composition Download PDFInfo
- Publication number
- CN113057329A CN113057329A CN202110379897.3A CN202110379897A CN113057329A CN 113057329 A CN113057329 A CN 113057329A CN 202110379897 A CN202110379897 A CN 202110379897A CN 113057329 A CN113057329 A CN 113057329A
- Authority
- CN
- China
- Prior art keywords
- functional
- glucoraphanin
- oligosaccharide
- dietary fiber
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RUQCCAGSFPUGSZ-OBWQKADXSA-N Glucoraphanin Natural products C[S@](=O)CCCCC(=NS(=O)(=O)O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RUQCCAGSFPUGSZ-OBWQKADXSA-N 0.000 title claims abstract description 57
- GMMLNKINDDUDCF-JRWRFYLSSA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1e)-5-[(r)-methylsulfinyl]-n-sulfooxypentanimidothioate Chemical compound C[S@@](=O)CCCC\C(=N/OS(O)(=O)=O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMMLNKINDDUDCF-JRWRFYLSSA-N 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 235000013376 functional food Nutrition 0.000 title claims abstract description 8
- 235000000346 sugar Nutrition 0.000 claims abstract description 38
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 25
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 16
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 16
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 16
- 235000016709 nutrition Nutrition 0.000 claims abstract description 8
- 230000036541 health Effects 0.000 claims abstract description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 10
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 9
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 9
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 9
- 244000068988 Glycine max Species 0.000 claims description 9
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 8
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 8
- 239000000811 xylitol Substances 0.000 claims description 8
- 235000010447 xylitol Nutrition 0.000 claims description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 8
- 229960002675 xylitol Drugs 0.000 claims description 8
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000000845 maltitol Substances 0.000 claims description 3
- 235000010449 maltitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
- 229940035436 maltitol Drugs 0.000 claims description 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 2
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 claims description 2
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 2
- 241001474374 Blennius Species 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 229920002752 Konjac Polymers 0.000 claims description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- 229920000294 Resistant starch Polymers 0.000 claims description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 239000000905 isomalt Substances 0.000 claims description 2
- 235000010439 isomalt Nutrition 0.000 claims description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 239000000252 konjac Substances 0.000 claims description 2
- 235000010485 konjac Nutrition 0.000 claims description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 2
- 229960000511 lactulose Drugs 0.000 claims description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- 235000021254 resistant starch Nutrition 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 230000035764 nutrition Effects 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 23
- 238000012360 testing method Methods 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 210000000628 antibody-producing cell Anatomy 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960005559 sulforaphane Drugs 0.000 description 2
- 235000015487 sulforaphane Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000019533 nutritive sweetener Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a glucoraphanin functional confectionary composition with a health-care effect, which comprises a glucoraphanin extract and functional sugar, wherein the functional sugar consists of functional dietary fibers, functional oligosaccharides and functional sugar alcohols; the food composition comprises 100-300 parts by weight of glucoraphanin extract, 100-300 parts by weight of functional dietary fiber, 0.015-0.1 part by weight of functional oligosaccharide and 5-30 parts by weight of functional sugar alcohol. The food composition can be used for preparing functional food with specific nutrition and health promotion functions.
Description
Technical Field
The invention relates to a food composition, in particular to a glucoraphanin functional confectionary composition, and belongs to the field of functional foods.
Background
A global survey by the world health organization indicates that truly healthy people account for only 5% of the population, that people with disease account for 20%, and that 75% are in sub-health. In 2004, 740 million cancer deaths worldwide accounted for about 13% of all deaths. WHO expects this number to continue to increase, and it is estimated that 1200 million people will die from cancer in 2030. The statistical data of the China Ministry of health show that: the total number of newly-increased tumor patients in China is about 212.7 million each year, and about 106 million newly-increased malignant tumor patients exist each year. The immune system is the natural barrier of the human body, can generate the immune protection function of maintaining the physiological balance of the organism and stabilizing the anti-tumor and the like, and the harmony of the immune system of the human body is the main reason of the natural regression of the cancer. Long-term hypoimmunity can lead to the development of cancer, and cancer patients are all the people with very low immunity.
The sulforaphane is used as aliphatic glucosinolate, is a natural active substance with the functions of enhancing immunity and resisting cancer, and has the maximum content of 20-50 mg/g in broccoli seeds. Therefore, the broccoli seed extract as a natural anti-cancer substance for enhancing immunity becomes a hot point for research of scholars at home and abroad. In 2017, 13-20% of broccoli seed aqueous extract containing sulforaphane is approved by the national committee of health care to be used as a new food raw material.
In recent years, with the continuous improvement of living standard of people, the dietary structure and the dietary habit of people are changed greatly. The intake of high calorie, high protein, high fat and fine food is greatly increased, and the intake of dietary fiber is relatively reduced. People neglect the balance of dietary nutrition, so that 'rich and noble diseases' -diabetes, cardiovascular diseases, obesity, intestinal cancer, constipation and the like are more and more common. Dietary fiber has been considered as a crude fiber having no nutritional value, but since the dietary fiber hypothesis proposed by burkittttrowell in the 70 th 20 th century, a number of studies have shown that dietary fiber has significant preventive and therapeutic effects on the above-mentioned various diseases. Dietary fiber is widely appreciated by experts from different fields, including medical scientists, dieticians, food scientists, biochemicals, and scientific deciders involved in food regulation and nutrition education, and is listed as the "seventh macronutrient" following carbohydrates, proteins, fats, water, minerals and vitamins. Many experts believe that fiber food will be one of the leading foods in the 21 st century.
The functional oligosaccharide is formed by polymerizing 2-10 monosaccharides through glycosidic bonds, cannot be degraded by gastric acid and gastric enzyme of a human body, cannot be absorbed by small intestines and can directly enter large intestines. The functional oligosaccharide can promote intestinal peristalsis, inhibit harmful bacteria, promote reproduction of probiotics and moisten intestines. With the rapid development of economy, people's demand for food is not only in the stage of satisfying satiety, and food with low energy, anti-caries, probiotic and other functions is more and more favored by consumers.
A functional sugar alcohol is a polyol that contains more than two hydroxyl groups and has some of the attributes of a sugar, although not a sugar. The functional sugar alcohol has higher stability to acid and heat, is not easy to generate Maillard reaction, is used as a low-calorific-value food sweetening agent, and is widely applied to sugar-free functional food formulas. Sugar alcohols have been used abroad in the food industry as sugar substitutes. Sugar alcohol is a good material for preventing dental caries because it is not utilized by microorganisms in the oral cavity. The sugar alcohol has no influence on the blood sugar value rise of a human body, and can provide a certain amount of heat for a diabetic, so the sugar alcohol can be used as a nutritive sweetener for the diabetic and the like. Sugar alcohols are now one of the unlimited use safe food products approved by the international food and health organization.
The inventor surprisingly discovers in research that the glucoraphanin functional sugar food composition combining the glucoraphanin extract and functional sugars such as functional dietary fibers, functional oligosaccharides, functional sugar alcohols and the like has the functions of remarkably improving the immunity and assisting in resisting tumors, has excellent effects and can be used for preparing functional foods with specific nutritional health-care functions.
Disclosure of Invention
The invention provides a glucoraphanin functional confectionary product composition, which is realized by the following technical scheme:
a glucoraphanin functional confectionery composition is provided, which includes a glucoraphanin extract and a functional sugar.
The functional sugar comprises functional dietary fiber, functional oligosaccharide and functional sugar alcohol.
The functional dietary fiber is at least one selected from soybean dietary fiber, seaweed dietary fiber, inulin, natural resistant starch, pectin, konjac polysaccharide, guar gum and chitin, the functional oligosaccharide is at least one selected from stachyose, raffinose, isomaltulose, lactulose, fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomalto-oligosaccharide, gentiooligosaccharide, soybean oligosaccharide and chitosan oligosaccharide, and the functional sugar alcohol is at least one selected from sorbitol, maltitol, xylitol, erythritol and isomalt.
In some embodiments, the glucoraphanin functional sugar food composition comprises the following ingredients in parts by weight:
further, the glucoraphanin functional sugar food composition comprises the following components in parts by weight:
furthermore, the glucoraphanin functional sugar food composition comprises the following components in parts by weight:
in some embodiments, the functional dietary fiber is soy dietary fiber, the functional oligosaccharide is stachyose, and the functional sugar alcohol is xylitol.
The glucoraphanin extract is obtained by extracting broccoli seeds and the glucoraphanin extract according to the proportion of 10-30: 1, and preferably the proportion of 20: 1.
The glucoraphanin functional sugar food composition has the functions of obviously improving the immunity and assisting in resisting tumors, and can be used for preparing functional food with specific nutrition and health-care functions.
The glucoraphanin functional sugar food composition provided by the invention has the advantages that glucoraphanin extract is used as a bidirectional regulator of the immune function, functional oligosaccharide is used as a microecological balance regulator, functional dietary fiber is used as a nutrition enhancer, and functional sugar alcohol is used as a low-calorific-value food sweetening agent, so that the immune function of the organism is jointly improved, the cancer prevention and anti-cancer capacity is assisted and enhanced, the immunity of the organism is enhanced through the synergistic effect from multiple aspects by the composition of a plurality of obvious functional factors, and the harmonious immune system of the organism is maintained.
The product of the invention has the following characteristics: 1) the compatibility is scientific: the glucoraphanin extract, the functional dietary fiber, the functional oligosaccharide and the functional sugar alcohol are scientifically combined. 2) The components are clear and the effect is definite: the product is rich in a plurality of bioactive substances such as glucoraphanin, functional dietary fiber, functional oligosaccharide, functional sugar alcohol and the like, and has definite effect. 3) Natural, safe and has no side effect.
The present invention is described in further detail below with reference to specific embodiments of examples, but it should not be construed that the present invention is limited to the examples, and the present invention based on the above description is within the scope of the present invention.
Detailed Description
Example 1: preparation of glucoraphanin functional sugar granules
The formula is as follows: 100mg of stachyose, 300g of glucoraphanin extract (broccoli seed 10:1), 300g of soybean dietary fiber and 30g of xylitol;
auxiliary materials: 400g of soluble starch and 450g of powdered sugar;
the preparation method comprises the following steps: mixing the above components with adjuvants such as soluble starch and sugar powder, granulating with water as binder, drying, grading to obtain food granule, and packaging to obtain 1.5 g/bag.
The taking method comprises the following steps: 1 bag each time and 1 time daily.
Example 2: preparation of glucoraphanin oral liquid
The formula is as follows: 100mg of stachyose, 80g of glucoraphanin extract (broccoli seeds 30:1), 170g of soybean dietary fiber and 10g of maltitol;
auxiliary materials: 600g of honey, 120g of xylitol and a proper amount of water;
the preparation method comprises the following steps: adding the above formula components and adjuvants into 5000ml water under stirring, heating to dissolve, filtering, adding water to 10000ml, sterilizing, and packaging into 10ml per bottle to obtain oral liquid preparation for food.
The taking method comprises the following steps: 1 daily, 1 branch each time.
Example 3: preparation of glucoraphanin functional sugar tablets
The formula is as follows: 60mg of stachyose, 200g of glucoraphanin extract (broccoli seed 20:1), 170g of soybean dietary fiber and 15g of xylitol;
auxiliary materials: 580g of dextrin, 40g of microcrystalline cellulose and 10g of magnesium stearate;
the preparation method comprises the following steps: mixing the above formula components, sieving with a 40 mesh sieve, adding dextrin and microcrystalline cellulose, mixing well, granulating with 50% ethanol as binder, drying, grading, adding magnesium stearate, mixing well, tabletting, and making into 0.25 g/tablet to obtain the glucoraphanin functional sugar tablet.
The taking method comprises the following steps: 2 tablets each time and 2 times daily.
Example 4: preparation of glucoraphanin functional sugar tablets
The formula is as follows: 60mg of stachyose, 200g of glucoraphanin extract (30: 1 of broccoli seeds), 170g of soybean dietary fiber and 15g of xylitol;
auxiliary materials: 288g of microcrystalline cellulose, 300g of lactose and 12g of magnesium stearate;
the preparation method comprises the following steps: mixing the above formula components, sieving with a 40 mesh sieve, adding microcrystalline cellulose, lactose, magnesium stearate and other adjuvants, mixing well, directly tabletting the powder, and making into 0.25 g/tablet to obtain food tablet.
The taking method comprises the following steps: 2 tablets each time and 2 times daily.
Example 5: functional test
The purpose of the test is as follows: checking whether the product has the function of enhancing immunity
Test materials:
sample preparation: the glucoraphanin prepared in example 3 is orally administered in a recommended amount of 0.25 g/tablet 2 times a day, 2 tablets each time. The adult body weight is calculated according to 60kg, and the equivalent dose is 0.017 g/kg-bw.
Test animals: 200 female mice of clean-grade Kunming species, with the weight of 18-22 g.
The test environmental conditions are as follows: a barrier system. The temperature is 22-24 ℃, and the humidity is 52-58%.
Dose selection and sample treatment: the low, medium and high dosages of the glucoraphanin functional sugar tablet prepared in example 3 were 0.08g/kg · bw, 0.17g/kg · bw and 0.50g/kg · bw, respectively (corresponding to 5, 10 and 30 times of the recommended dosage for human body). When preparing low, medium and high dose test solutions, 0.8g, 1.7g and 5.0g of the glucoraphanin functional sugar tablets prepared in the embodiment 3 are respectively added with distilled water to be constant volume to 200mL, the same volume of distilled water is added to a control group, the test animals are respectively subjected to intragastric gavage, the intragastric gavage is performed once a day, the intragastric volume is 0.2mL/kg · bw, and the continuous 30 days are carried out.
Main apparatus and reagents: an animal platform scale, an analytical balance, a clean bench, a carbon dioxide incubator, an autoclave, a filter, a centrifuge, a 722 spectrophotometer, a constant temperature water bath, a microplate reader, a microscope and the like.
The test method comprises the following steps: the functional evaluation was carried out by organ/body weight ratio measurement, delayed type allergy, ConA-induced lymphocyte transformation test in mice, antibody-producing cell detection, measurement of median hemolysis value, carbon clearance test in mice, phagocytosis of chicken erythrocytes by macrophages in mouse abdominal cavity, and NK cell activity measurement test.
And (3) test results:
when the glucoraphanin prepared in example 3 is orally administered to mice at doses of 0.08 g/kg/bw, 0.17 g/kg/bw and 0.50 g/kg/bw for 30 days, the doses of 0.17 g/kg/bw and 0.50 g/kg/bw can enhance delayed-type allergic reaction of the mice, increase the number of antibody-producing cells of the mice and increase the activity of NK cells of the mice, and the dose of 0.50 g/kg/bw can increase the carbon clearance capacity of mononuclear-macrophages of the mice, increase the lymphocyte transformation capacity of the mice and increase the half hemolysis value of serum of the mice, wherein P is less than 0.05. No significant effect was observed on the mouse body weight gain, spleen/body weight ratio, thymus/body weight ratio, ability of macrophages to phagocytose chicken erythrocytes (P > 0.05). Under the experimental condition, the sample is suggested to have the function of enhancing the immunity.
The specific test results data are shown in the following table:
table 1: example 3 Effect of glucoraphanin-A-functional sugar tablets on delayed type allergy (DTH) in mice
As can be seen from Table 1, when different doses of the glucoraphanin functional sugar tablets are orally administered to the mice for 30 days, the degree of foot sole swelling of the medium and high dose groups is obviously higher than that of the control group, and the difference is significant (P < 0.05).
Table 2: example 3 Effect of the food Capsule prepared in example 3 on mouse ConA-induced mouse lymphocyte transformation Capacity test
As can be seen from Table 2, when the different doses of the glucoraphanin functional sugar tablets are orally administered to the mice for 30 days, the lymphocyte transformation capacity of the mice in the high dose group is obviously higher than that of the mice in the control group, and the difference is significant (P < 0.05).
Table 3: example 3 Effect of the glucoraphanin-A-functional sugar tablets prepared in example 3 on the number of mouse antibody-producing cells
As can be seen from Table 3, when the different doses of the glucoraphanin functional sugar tablets were orally administered to the mice for 30 days, the number of antibody-producing cells in the medium and high dose groups was significantly higher than that in the control group, and the difference was significant (P < 0.05).
Table 4: effect of glucoraphanin prepared in example 3 on half-maximal hemolysis value (HC50) of mouse
As can be seen from Table 4, when the different doses of the glucoraphanin functional sugar tablets are orally administered to the mice for 30 days, the half hemolysis value of the mice in the high dose group is obviously higher than that of the control group, and the difference is significant (P < 0.05).
Table 5: example 3 Effect of glucoraphanin-functional sugar tablets on mouse monocyte-macrophage carbon clearance
As shown in Table 5, when the different doses of the glucoraphanin functional sugar tablets are orally administered to the mice for 30 days, the phagocytosis index of the mice in the high dose group is obviously higher than that of the control group, and the difference is significant (P < 0.05).
Table 6: example 3 Effect of glucoraphanin functional sugar tablets on NK cell Activity in mice
As can be seen from Table 6, when the mice are orally administered with different dosages of the glucoraphanin functional sugar tablets for 30 days, the NK cell activity of the mice in the medium and high dose groups is obviously higher than that of the control group, and the difference is significant (P < 0.05).
Example 6: functional test
The purpose of the test is as follows: checking whether the product has the function of auxiliary inhibiting tumor growth
Test materials:
sample preparation: the glucoraphanin prepared in example 4 is orally administered in a recommended amount of 0.25 g/granule 2 times a day, 2 granules each time. The adult body weight is calculated according to 60kg, and the equivalent dose is 0.017 g/kg-bw.
Test animals: 100 male mice of clean-grade Kunming species, with the body weight of 18-22 g.
The test environmental conditions are as follows: a barrier system. The temperature is 22-24 ℃, and the humidity is 52-58%.
The main apparatus is as follows: an animal platform scale, an analytical balance, a clean bench, a carbon dioxide incubator, an autoclave, a centrifuge, a microscope and the like.
The test method comprises the following steps: a suspension of H22 tumor cells (1X 105) was inoculated subcutaneously into the axilla of the forelimb of animals at a rate of 0.2 ml/mouse for a total of 70 mice. After 24h the weights were randomly divided into 7 groups: the test drugs (the glucoraphanin functional sugar tablets prepared in example 4 are 0.08 g/kg-bw and 0.50 g/kg-bw), cyclophosphamide (CY, 0.03 g/kg-bw) and positive control (CY, 0.03 g/kg-bw) are added into groups of 10 test drugs (10 glucoraphanin functional sugar tablets prepared in example 4 are divided into groups and then administered, the test drugs are filled into the stomach, and the test drugs are injected into the abdominal cavity once a day for 10 days and administered every other day. The general status of each group of mice was observed daily. The next day after drug withdrawal, each group of animals was weighed, mice were sacrificed and tumor mass was stripped off, weighed and tumor inhibition rate was calculated.
The specific test results data are shown in the following table:
table 7: EXAMPLE 4 inhibitory Effect of glucoraphanin-A functional sugar tablet prepared in example 4 on mouse H22 tumor
Note: (ii) 0.05, 0.01 as compared to tumor control group; compared with the cyclophosphamide group, the delta is less than 0.05, and the delta is less than 0.01.
After tumor inoculation, the number of times of animal activities of the mice in the model group and the positive control group is obviously reduced, the skin is loose, the hair is upright, and the state is poor. The mice with the single test drug group and the combination of cyclophosphamide group have normal activity, smooth skin and hair and weight gain. The positive control medicine can obviously inhibit the growth of tumors, but the weight of animals is slowly increased, and the state is poor. The tested drug has the effect of inhibiting the growth of the H22 tumor when being used alone, and the tumor inhibition rate is 29.6 percent; the effect is strengthened after the composition is used with the chemotherapeutic drug cyclophosphamide, the tumor inhibition rate is 64.8 percent, and the inhibition rate of cyclophosphamide on H22 tumor is 59.8 percent. Meanwhile, the sample can also increase spleen and thymus index of tumor-bearing mice, promote weight gain of the mice, and has obvious difference compared with a tumor control group and a cyclophosphamide group, which indicates that the sample has protective effect on immune organs of the tumor-bearing mice in chemotherapy and has synergistic attenuation effect when being used with chemotherapeutic drugs. Under the experimental condition, the sample is suggested to have the function of assisting in inhibiting the growth of the tumor.
Claims (9)
1. A glucoraphanin functional confectionary composition is characterized by comprising glucoraphanin extract and functional sugar.
2. The glucoraphanin functional confectionery composition of claim 1, wherein the functional sugar comprises functional dietary fiber, functional oligosaccharide and functional sugar alcohol.
3. A glucoraphanin functional confectionery composition according to claim 2, wherein the functional dietary fiber is selected from at least one of soybean dietary fiber, seaweed dietary fiber, inulin, natural resistant starch, pectin, konjac polysaccharide, guar gum, chitin, the functional oligosaccharide is selected from at least one of stachyose, raffinose, isomaltulose, lactulose, fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomalto-oligosaccharide, gentiooligosaccharide, soybean oligosaccharide, oligochitosan, the functional sugar alcohol is selected from at least one of sorbitol, maltitol, xylitol, erythritol, isomalt.
4. A glucoraphanin functional confectionery composition according to claim 2 or 3, comprising the following ingredients in parts by weight:
5. the glucoraphanin functional confectionery composition of claim 4, comprising the following ingredients in parts by weight:
6. a glucoraphanin functional confectionary composition of claim 5 comprising the following ingredients in parts by weight:
7. a functional glucoraphanin composition according to any one of claims 3-6, characterized in that the functional dietary fiber is soybean dietary fiber, the functional oligosaccharide is stachyose, and the functional sugar alcohol is xylitol.
8. A functional glucoraphanin composition according to any one of claims 1-7, wherein the glucoraphanin extract is extracted from broccoli seeds and the glucoraphanin extract at a ratio of 10-30: 1, preferably 20: 1.
9. Use of the glucoraphanin functional sugar food composition according to any one of claims 1 to 8 for preparing a functional food having a specific nutritional health function.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110379897.3A CN113057329A (en) | 2021-04-08 | 2021-04-08 | Glucoraphanin functional food composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110379897.3A CN113057329A (en) | 2021-04-08 | 2021-04-08 | Glucoraphanin functional food composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113057329A true CN113057329A (en) | 2021-07-02 |
Family
ID=76566523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110379897.3A Pending CN113057329A (en) | 2021-04-08 | 2021-04-08 | Glucoraphanin functional food composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113057329A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108294211A (en) * | 2018-02-02 | 2018-07-20 | 云南瑞宝生物科技股份有限公司 | A kind of functional solid beverage and preparation method thereof containing glucorphanin |
| CN111419857A (en) * | 2016-06-30 | 2020-07-17 | 深圳福山生物科技有限公司 | Glucoraphanin composition and application thereof |
-
2021
- 2021-04-08 CN CN202110379897.3A patent/CN113057329A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111419857A (en) * | 2016-06-30 | 2020-07-17 | 深圳福山生物科技有限公司 | Glucoraphanin composition and application thereof |
| CN108294211A (en) * | 2018-02-02 | 2018-07-20 | 云南瑞宝生物科技股份有限公司 | A kind of functional solid beverage and preparation method thereof containing glucorphanin |
Non-Patent Citations (1)
| Title |
|---|
| 公茂勇，等: "不同种质萝卜肉质根硫苷组分及含量分析", 《南京农业大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104643250A (en) | Solid beverage capable of bidirectionally regulating body weight and improving subhealth | |
| CN106901367A (en) | The composition and preparation method and purposes of a kind of balance blood sugar | |
| CN102600212A (en) | Medicinal health product for immunity enhancement and adjuvant treatment of tumor | |
| CN107048164A (en) | A kind of low sugar rice cake | |
| CN106723015A (en) | A kind of health food and its preparation technology with antifatigue and anti-oxidation function | |
| KR101614574B1 (en) | Composition of Diabetes-Improving Effective Constituents by Fermentation Products of the Trifoliate Orange | |
| CN106901375A (en) | It is a kind of compound for sugar product containing xylitol | |
| CN103637185A (en) | Nervonic acid composition | |
| KR101829637B1 (en) | A composition for improving, preventing and treating digestion dysfunction, leukocyte reduce, bone marrow suppression by side effects after anti-cancer therapy comprising Rhus verniciflua stoke extract | |
| CN107551001B (en) | A Chinese medicinal composition for preventing and treating alcoholic hepatic injury and its preparation method | |
| CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
| CN105433382B (en) | A kind of maca composition and its preparation method and application | |
| CN111357891A (en) | Plant beverage containing artichoke and ginseng and preparation method thereof | |
| CN103417799B (en) | A kind of application of Chinese medicine composition in the medicine for preparing treatment anaemia | |
| CN113057329A (en) | Glucoraphanin functional food composition | |
| CN111616357B (en) | GABA spleen-tonifying and nerve-soothing composition based on homology of medicine and food, preparation and application thereof | |
| CN115104736A (en) | Breast milk oligosaccharide and probiotic composition and application thereof in promoting digestion and absorption | |
| CN106255502A (en) | Satiety continues agent and makes the lasting method of satiety | |
| CN111685332A (en) | Composition with fat-reducing, body-shaping and body-beautifying functions and preparation method thereof | |
| WO2014134830A1 (en) | Edible composition, food product comprising same, and preparation method for the food product | |
| CN113068829A (en) | Health food for invigorating spleen, promoting digestion and improving immunity, and preparation method and application thereof | |
| CN113842452A (en) | Medicine composition for treating diabetes and preparation method thereof | |
| CN110548109B (en) | Traditional Chinese medicine composition for treating child anorexia and preparation method thereof | |
| CN112690449A (en) | Cereal conditioning porridge for middle-aged and old people | |
| CN112690386A (en) | A dietetic composition with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular and immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210702 |